Tag: average sales price

WASHINGTON - Seven codes for Medicare Part B drugs met CMS's price substitution criteria by exceeding the 5% threshold for two consecutive quarters or three of the previous four quarters, according to a new report from the Office of Inspector General. The OIG is providing the seven codes to CMS for its review. It says CMS should review this information to determine whether or not to pursue price substitutions that would limit excessive payments for Part B drugs. The OIG conducted its study by obtaining...

WASHINGTON - The average sales price for 11 drug codes for the second quarter of 2019 exceeded the average manufacture price by 5% or more for two consecutive quarters, according to a new report from the Office of Inspector General. Another 11 codes exceeded the 5% threshold in the second quarter, but did not meet other price-substitution criteria. When the ASP exceeds the AMP by 5%, the Department of Health and Human Services substitutes the ASP-based amount with a lower calculated rate, either...

WASHINGTON - The average sales price for 10 drug codes for the fourth quarter of 2018 exceeded the average manufacture price by 5% or more for two consecutive quarters, according to a new report from the Office of Inspector General. Another five drug codes exceeded the AMP by at least 5% during the quarter but did not meet other price substitution criteria. When the ASP exceeds the AMP by 5%, the Department of Health and Human Services substitutes the ASP-based amount with a lower calculated rate,...

WASHINGTON - The National Home Infusion Association seeks signatures for a letter that urges Congress to align the effective dates of switching to an average sales price reimbursement model for Part B infusion drugs.In the letter, addressed to Senate Majority Leader Mitch McConnell, Senate Minority Leader Charles Schumer, House Speaker Paul Ryan and Democratic Leader Nancy Pelosi, the association requests “quick action” to ensure beneficiaries have access to services, equipment and drugs.“The...

WASHINGTON - HME stakeholders have added two co-sponsors to a bill in the Senate that would delay a second round of Medicare reimbursement cuts slated for July 1.Sens. Debbie Stabenow, D-Mich., and James Lankford, R-Okla., signed on to S. 2736 on April 6. They join 15 other senators, a mix of Democrats and Republicans.The bill, introduced by Sens. John Thune, R-S.D., and Heidi Heitkamp, D-N.C., on March 17, would delay the cuts slated for non-competitive bidding areas from July 1, 2016, to Oct. 1,...

BALTIMORE - Second quarter payments for respiratory drugs are up in most cases, with the exception of Budesonide (J7626), which decreased sharply, down nearly 73 cents per dose. Perforomist (J7606) saw the biggest increase, up 41 cents to $9.82 per dose, according to the latest average sales price (ASP) figures. Brovana (J7605) increased 24 cents to $8.50 per dose. Albuterol (J7613) and ipratropium (J7644) stayed fairly flat, at 12.5 cents per dose and 10.5 cents per dose, respectively.

WASHINGTON - The House of Representatives on June 17 passed a bill that included a provision that would switch payment for Part B home infusion drugs to an average sales price model—a model that is unsustainable, say infusion stakeholders.“The services that are associated with Part B infusion drugs are not reflected in the policy lawmakers are moving forward,” said Kendall van Pool, vice president of legislative affairs for the National Home Infusion Association. “If this...

MIAMI - A federal judge has ruled that two former Lincare employees failed to prove the provider violated Medicare telemarketing rules.U.S. District Judge Kathleen Williams on July 10 issued a partial summary judgment that freed Lincare from most of the charges outlined in a whistleblower lawsuit accusing the provider of violating the False Claims Act.The plaintiffs had argued that Lincare and its subsidiary, Diabetic Experts, violated Medicare rules by using improper sales leads to make unsolicited...

BALTIMORE - Third-quarter payments for respiratory drugs are up and down. Brand name drugs Brovana (J7605) and Perforomist (J7606) were up 16 cents and nearly 44 cents to $7.20 and $8.48 per dose, respectively. Payments for budesonide (J7626) were down nearly 38 cents to $5.20 per dose and payments for albuterol (J7613) were cut in half to 13.5 cents per dose. Ipratropium (J7644) stayed relatively flat at just under 11 cents per dose.

BALTIMORE - Fourth-quarter payments for respiratory drugs is up nearly across the board. Brand name drug Perforomist (J7606) saw the biggest jump, up nearly 90 cents, to $7.46 per dose according to the latest average sales price (ASP) figures. Brovana (J7605) increased to $6.96, up 57 cents from the previous quarter; and budesonide (J7626) increased nearly 48 cents to $5.38 cents per dose. Albuterol (J7613) and ipratropium (J7644) stayed relatively flat, at 14 cents per dose and just under 12 cents...